CoChat

Cannabinoids therapeutic use: what is our current understanding following the introduction of THC, THC:CBD oromucosal spray and others?

Maccarrone, Mauro, Maldonado, Rafael, Casas, Miguel, Henze, Thomas, Centonze, Diego · 2017 · Expert Review of Clinical Pharmacology
Cited by 80

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Abstract

Mauro Maccarroneab , Rafael Maldonadoc, Miguel Casasdef, Thomas Henzeg & Diego CentonzehDepartment of Medicine, Campus Bio-Medico University of Rome , Rome, Italy Laboratory of Lipid Neurochemistry, European Center for Brain Research/IRCCS Santa Lucia Foundation , Rome, Italy Laboratori de Neurofarmacologia, Departament de Ciències Experimentals i de la Salut (CEXS), Facultat de Ciències de la Salut i de la Vida, Universitat Pompeu Fabra , Barcelona, Spain Servicio de Psiquiatría, Hospital Universitari Vall d’Hebron , Barcelona, Spain Departamento de Psiquiatría y Medicina Legal, Universitat Autònoma de Barcelona , Barcelona, Spain CIBERSAM , Barcelona, Spain Passauer Wolf Reha-Zentrum Nittenau , Nittenau, Germany Multiple Sclerosis Clinical and Research Center, Tor Vergata University, Rome & Unit of Neurology, IRCCS Istituto Neurologico Mediterraneo Neuromed , Pozzilli, Italy CONTACT Mauro Maccarrone m.maccarrone@unicampus.it Department of Medicine, Campus Bio-Medico University of Rome , Via Alvaro del Portillo 21, 00128 Rome, Italy, ABSTRACT Introduction: The complexity of the endocannabinoid (eCB) system is becoming better understood and new drivers of eCB signaling are emerging. Modulation of the activities of the eCB system can be therapeutic in a number of diseases. Research into the eCB system has been paralleled by the development of agents that interact with cannabinoid receptors. In this regard it should be remembered that herbal cannabis contains a myriad of active ingredients, and the individual cannabinoids have quite distinct biological activities requiring independent studies. Areas covered: This article reviews the most important current data involving the eCB system in relation to human diseases, to reflect the present (based mainly on the most used prescription cannabinoid medicine, THC/CBD oromucosal spray) and potential future uses of cannabinoid-based therapy. Expert commentary: From the different therapeutic possibilities, THC/CBD oromucosal spray has been in clinical use for approximately five years in numerous countries world-wide for the management of multiple sclerosis (MS)-related moderate to severe resistant spasticity. Clinical trials have confirmed its efficacy and tolerability. Other diseases in which different cannabinoids are currently being investigated include various pain states, Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and epilepsy. The continued characterization of individual cannabinoids in different diseases remains important.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/17512433.2017.1292849

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 80

Metadata

Authors
Maccarrone, M., Maldonado, R., Casas, M., Henze, T., & Centonze, D.
Venue
Expert Review of Clinical Pharmacology
Published
2017-02-28
Volume
10
Issue
4
Pages
443-455
ISSN
  • 1751-2433 (ISSN-L)
  • 1751-2441
OpenAlex
W2586473686
Cited by
80
References
34
FWCI
8.01
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.